Hypertension News, Research Articles | HBP & Renal Disorder Treatment



Phosphate Binders Cut Mortality, Up ESRD Risk

Potassium Binder May Enable Optimal RAASi Use in CKD

In a study, 87% of hyperkalemic patients on renin-angiotensin-aldosterone system inhibitor (RAASi) therapy were able to continue or increase their RAASi doses while concurrently taking sodium zirconium cyclosilicate.
Next post in News